Terms: = Pancreatic cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Clinical Outcome
3 results:
1. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting fasL.
Wang P; Zhuang L; Zhang J; Fan J; Luo J; Chen H; Wang K; Liu L; Chen Z; Meng Z
Mol Oncol; 2013 Jun; 7(3):334-45. PubMed ID: 23177026
[TBL] [Abstract] [Full Text] [Related]
2. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI).
Schmidt J; Patrut EM; Ma J; Jäger D; Knaebel HP; Büchler MW; Märten A
Cancer Immunol Immunother; 2006 Nov; 55(11):1396-405. PubMed ID: 16485127
[TBL] [Abstract] [Full Text] [Related]
3. Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
Ma JH; Patrut E; Schmidt J; Knaebel HP; Büchler MW; Märten A
World J Gastroenterol; 2005 Mar; 11(10):1521-8. PubMed ID: 15770730
[TBL] [Abstract] [Full Text] [Related]